Download full announcement

For the purposes of DTR5.6.1R of the Transparency Directive, the Company notifies the market of the following:

As of 31 July 2019, the Company’s issued and fully paid share capital consists of 59,416,134 ordinary shares with a nominal value of £0.0025 each (“Ordinary Shares”), with one voting right per share. The Company does not hold any Ordinary Shares in Treasury. The total number of voting rights in the Company is therefore 59,416,134.

The above figure of 59,416,134 should be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.

Enquiries

About Kidney Disease 

Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. In the United States alone, over 40 million people are classified as having chronic kidney disease, with nearly 50 percent of individuals with advanced (Stage IV) disease unaware of the severity of their reduced kidney function. As a result, many patients progress to kidney failure in an unplanned manner, ending up having dialysis in the emergency room without ever seeing a clinical specialist, such as a nephrologist. Every day 13 patients die in the United States while waiting for a kidney transplant.

About RenalytixAI

RenalytixAI is a developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. For more information, visit renalytixai.com.